Bourne Partners Strategic Capital

Bourne Partners Strategic Capital is a private equity firm specializing in middle-market healthcare investments. The firm focuses on operationally intensive, control-oriented investments in the pharmaceutical, pharma services, and consumer health sectors. With over 20 years of experience, Bourne Partners seeks to partner with management teams and other stakeholders to drive growth and value creation.

The firm's investment strategy emphasizes flexibility and discipline, targeting cash flow-positive opportunities in growth-stage or middle-market businesses. Bourne Partners has a proven track record, with an average multiple of invested capital (MOIC) exceeding 8x on exited investments. Their approach includes sourcing acquisitions, leveraging strategic relationships, providing operational solutions, and fostering long-term partnerships to enhance portfolio company performance.

Bourne Partners Strategic Capital's portfolio includes investments in companies such as Covis Pharma, Tanner Pharma Group, Curia, Theramed Specialty Pharmaceuticals, Carlin Consumer Health, Pharmaceutical Associates, Inc. (PAI), iNova Pharmaceuticals, Novitium Pharma, Millicent Pharma, Cadence Rx, WellDyneRx, MedPharm, Eximia, and American Injectables. These investments reflect the firm's commitment to enhancing the lives and well-being of partners and patients globally by facilitating the efficient movement of capital through the healthcare sector.